Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706077 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL249120 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12525029 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12524998 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL14980914 | 0.82 | SMN1; SMN2 (0.38) | CYP2C9CYP2C19SMN1; SMN2GBA1CA2 | |
| SCHEMBL23841973 | 0.80 | CYP2C9 (0.41) | CYP2C9CYP2C19CA2GAAALDH1A1 | |
| SCHEMBL135940 | 0.77 | CA2 (0.40) | CYP2C9CYP2C19SMN1; SMN2CA2GAA | |
| SCHEMBL1443275 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL14508491 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL2798313 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106147887-B | Methanol gasoline multiphase corrosion inhibitor and methanol gasoline prepared from same | 福建中源新能源股份有限公司 | 2018-05-04 | — | — | CN | claimed |
| CN-106147887-A | Methanol gasoline multiphase corrosion inhibitor and methanol gasoline prepared from same | 福建中源新能源股份有限公司 | 2016-11-23 | — | — | CN | claimed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230233546-A1 | METHODS OF TREATING CANCER | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023114933-A1 | METHODS OF TREATING CANCER | KYMERA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-105189524-B | The synthetic method of optical activity alpha-amino acid | 浜理药品工业株式会社 | 2019-07-19 | — | — | CN | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-5250522-A | Neutral endopeptidase inhibitors; cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233546-A1 | METHODS OF TREATING CANCER | TP53, MDM2, MCL1 | CYP2C9 3919/4885CYP2C19 3827/4885SMN1; SMN2 1499/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CYP2C9 2267/4885CYP2C19 2181/4885SMN1; SMN2 3149/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | CYP2C9 2267/4885CYP2C19 2181/4885SMN1; SMN2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.